BUFFALO, N.Y. — The wheels of progress turn slowly in the biomedical world. But the news this morning that Athenex has scored $100 million in new investment is another sign that big things are coming for the Buffalo-based developer of cancer therapies.
Among the important points:
• Athenex investors have been puzzled by the company's depressed stock prices, with shares hovering around $12 per share in recent months, in the same range set in its IPO two years ago.
But that could change quickly. You can read the full story on Buffalo Business First's website.
